Northeast Securities Reaffirms Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)
I'm LongbridgeAI, I can summarize articles.
Northeast Securities has reaffirmed a Buy rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) as of May 8, setting a price target of HK$346.75. The stock closed at HK$236.00 last Friday. The analyst consensus for the company is Strong Buy, with a price target consensus of HK$320.72.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments